Skin AgeingIDF-AID-1NCT07827651
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
A study testing Advanced ID in people with Skin Ageing and Healthy Ageing, run by IDI Skincare Limited at 1 site in United Kingdom.
Trial summary
This study evaluated the effects of a daily oral supplement regimen (Advanced ID Brain, Heart and Eye Omega Gel Capsules taken with Advanced ID Longevity and Collagen Complex Powder) on measures of skin condition, hair, sleep, energy, cognition and sexual wellbeing in healthy adults aged 35 to 65 years. Read more about this study
- Who is it for?
- Ages 35 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults
- What is being tested?
- Advanced ID
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 8 Dec 2025to 30 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy adults aged 35 to 65 years (30% male : 70% female desired)
- In generally good health, as determined by medical history questionnaire
- Free from excessive hair, tattoos, dermatitis or scars on the test areas; males must attend each visit clean shaven, having shaved the day before the appointment
- Able to read, understand and sign an informed consent agreement
- Able to communicate well with study personnel and comply with study requirements
- Hair at least 3 cm long, with no intention of substantial change to hair style
Show all 20Show fewer
- Participants on medicinal contraception: stable method for at least 3 months prior to baseline and willing not to change for the study duration
- Women of childbearing potential: willing to use a reliable method of contraception
- Participants on hormone replacement therapy (HRT): stable HRT for at least 6 months prior to baseline and willing not to change
- Willing not to change regular food habits or commence any diet or nutritional change
- Willing to refrain from taking any new dietary supplements other than study products
- Willing to maintain usual lifestyle habits including exercise regimes
- Willing to avoid medicated shampoo and conditioner
- Willing to refrain from dermato-aesthetic facial procedures
- Willing to refrain from chemical hair styling procedures (colour treatments permitted)
- Willing to avoid excessive natural sunlight and other avoidable UV sources
- Willing to remove facial piercings, earrings or jewellery prior to imaging
- Willing to consent to use of their images by the Sponsor
- Willing to have photographs taken to record any significant reactions
- Willing to adhere to all study restrictions and requirements
Who cannot join
- - Pregnant, breastfeeding, or of childbearing potential and not using reliable contraception
- Consumed any food or health supplements (including vitamins, creatine, omegas, collagen) within the 3 months prior to baseline
- Known allergy or hypersensitivity to any study product ingredient (products contain fish and coconut ingredients)
- Known allergy or hypersensitivity to any dietary supplements
- Any systemic condition (acute or chronic) or skin disorder including eczema, psoriasis, acne or diabetes (inactive skin disease for at least 6 months prior to baseline may be accepted at the Project Manager's discretion)
- History of skin cancer with remission period below 5 years
Show all 32Show fewer
- Asthma or other chronic respiratory condition requiring therapy within the last 6 months
- Any other systemic disease or medical or skin condition which in the opinion of the Project Manager, Study Doctor or Sponsor would affect ability to complete the study
- Diagnosis of high cholesterol (current or previous)
- Current treatment with cholesterol lowering medication
- Family history of high cholesterol (first degree relative)
- Diagnosis of ischaemic heart disease (current or previous)
- Diagnosis of peripheral vascular disease or intermittent claudication
- Diagnosis of stroke (current or previous)
- Treatment (oral or topical) with tretinoin, isotretinoin or corticosteroids within the 6 months prior to baseline
- Systemic steroids or anti-inflammatory treatments within the 6 months prior to baseline
- Medications which may affect sampling or analysis, including metformin, anticoagulants, biological therapies, immunosuppressive or immunomodulating medication, chemotherapy, cytokine or anti-cytokine therapy
- Surgical or non-surgical dermato-aesthetic facial procedures within the 6 months prior to baseline
- Facial surgery (excluding dental) within the previous 6 months
- Diagnosis of facial nerve damage
- False eyelashes of any type on assessment days
- Refusal to remove eyebrow make-up
- Facial or ear piercings that cannot be removed for assessments
- Low protein diet
- Vegetarian or vegan diet (study products contain marine collagen and bovine gelatine)
- Average alcohol consumption greater than 14 units per week
- Night shift workers or irregular working hours interfering with regular sleep pattern
- Intention to commence smoking cessation activities or alternative nicotine products during the study
- Medically diagnosed insomnia
- Active medically diagnosed alopecia or previous history
- History of or high risk of blood borne infection (HIV, hepatitis B or C, AIDS)
- History of problematic blood collections or negative experience during surgery
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Eurofins Product Testing Services Ltd (Eurofins Alba)
Edinburgh, EH1 3RH
About this study
Official title: A Double-Blind, Randomised, Placebo-Controlled Study Evaluating the Effects of a Novel Multi-Targeted Dermatologist-Formulated Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido, and Longevity
This study evaluated the effects of a daily oral supplement regimen (Advanced ID Brain, Heart and Eye Omega Gel Capsules taken with Advanced ID Longevity and Collagen Complex Powder) on measures of skin condition, hair, sleep, energy, cognition and sexual wellbeing in healthy adults aged 35 to 65 years.
Participants were randomised in a 2:1 ratio to receive either the active supplement regimen or a matched placebo regimen once daily with food for 12 weeks. Instrumental skin measurements, trained-assessor visual grading and participant questionnaires were performed at baseline (Day 0), Day 28 and Day 84. Hair imaging and cognitive testing were performed at baseline and Day 84. Whole blood samples were collected at baseline and Day 84 for exploratory epigenetic DNA biological clock age analysis, reported separately.
The study was single-centre, sponsored by IDI Skincare Limited and conducted by Eurofins Product Testing Services Ltd (trading as Eurofins Alba) in Edinburgh, United Kingdom.
Read the detailed description
Study conduct
The study was conducted at a single centre over 12 weeks with three clinic visits: baseline (Day 0), Day 28 and Day 84. At each of the first two visits participants received a four-week supply of their allocated study products together with a diary sheet to record daily consumption and compliance. Participants consumed their allocated products once daily in the morning with food at home. An acclimatisation period preceded instrumental measurements and imaging at each assessment visit. Adverse events were recorded throughout the study period.
Randomisation and blinding
The randomisation schedule was generated by an independent statistician using product codes only, via a centralised electronic randomisation system, with provision for emergency unblinding. Participants and assessors remained blinded to allocation throughout. Analysts were blinded to product identity at the time of statistical analysis.
Sample size
Enrolment of a minimum of 60 healthy participants was planned in order to complete with a minimum of 50 evaluable participants, targeting a 2:1 completion ratio between the active and placebo groups. The sample size was set on feasibility grounds rather than by formal power calculation.
Statistical analysis
Quantitative responses were modelled as within-subject changes from baseline using mixed models with subject as a random effect, fitted in R, with covariates comprising baseline response level, time, product and their interaction. Handling of baseline measures followed European Medicines Agency (2013) guidance. Where only a single post-baseline measure existed, a simple linear model was fitted. Questionnaire data were analysed non-parametrically where distributional assumptions were violated. Statistical significance was defined at the 5% level. No adjustment for multiple comparisons was applied, and results should be interpreted accordingly given the number of endpoints assessed.
- Conditions
- Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity, Healthspan Improvement, Cognitive Processing Speed
- Being tested
- Advanced ID, Placebo Control
- Keywords
- collagen, dietary supplement, omega-3, skin elasticity, skin hydration, transepidermal water loss, hair density, sleep quality, cognition, healthy volunteers, healthspan, longevity, sleep, recovery, biological age, biological clock age, aging, ageing
- Medical subject headings
- Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Advanced IDDietary supplement
Also called Advanced ID Brain, Heart and Eye Omega Gel Capsules, Advanced ID Longevity and Collagen Complex Powder
Combined regimen of Advanced ID Brain, Heart and Eye Omega Gel Capsules and Advanced ID Longevity and Collagen Complex Powder. Contains marine collagen (fish) and bovine gelatine.
Placebo ControlDietary supplement
Virgin coconut oil softgel capsules and maltodextrin powder, matched in presentation to the active regimen.
| Study group | Role | What they receive |
|---|---|---|
| Advanced ID Longevity and Collagen Complex Powder | Experimental | Two Advanced ID Brain, Heart and Eye Omega Gel Capsules followed by approximately 12 g (one scoop) Advanced ID Longevity and Collagen Complex Powder mixed with 400 ml water, taken orally once daily in the morning with food for 12 weeks. Receives: Dietary Supplement: Advanced ID |
| Placebo Control | Placebo comparator | Two VitaMinute (brand name) Organic Virgin Coconut Oil Softgel Capsules followed by approximately 12 g (one scoop) maltodextrin mixed with 400 ml water, taken orally once daily in the morning with food for 12 weeks. Receives: Dietary Supplement: Placebo Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in skin elasticity
Measured by Cutometer, left and right cheeks and centre forehead.
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in skin firmness
Measured by Cutometer, left and right cheeks and centre forehead
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in skin hydration
Measured by Corneometer, left and right cheeks and centre forehead
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in skin barrier function
Transepidermal water loss (TEWL) measured by DermaLab SkinLab USB Series TEWL Probe, left and right cheeks and centre forehead
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in skin radiance
Trained assessor global assessment using Visual Analogue Scale. Lower scores indicate greater skin radiance/brightness. Higher scores indicate duller, less radiant skin. Therefore, a reduction from baseline indicates improvement. Minimum value is 0 and maximum is 9.
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in fine lines and wrinkles
Trained assessor grading using Roland Bazin scales for crow's feet wrinkles, crow's feet wrinkle depth and number, forehead wrinkles, glabella wrinkles and underneath eye wrinkles. Higher scores indicate greater wrinkle severity. Therefore, a reduction from baseline indicates improvement. Min value is 0, max is 5-7 (depending on the wrinkle scale assessed).
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in hair density
C-Cube 2D image acquisition and analysis
Measured: Baseline (Day 0), Day 84
Change from baseline in hair shaft thickness
C-Cube 2D image acquisition and analysis
Measured: Baseline (Day 0), Day 84
Change from baseline in hair count
Baseline (Day 0), Day 84
Measured: Baseline (Day 0), Day 84
Secondary outcomes (4)
Change from baseline in sleep quality
Pittsburgh Sleep Quality Index (PSQI) score. Lower scores indicate better sleep quality.
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in perceived vitality and energy
RAND-36 (RAND 36-Item Health Survey 1.0) Vitality subscore (four-question set). Higher scores indicate greater vitality and energy (better outcome). Min is 0, Max is 100.
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in sexual wellbeing
Arizona Sexual Experiences Scale (ASEX). Higher scores indicate greater sexual dysfunction.
Measured: Baseline (Day 0), Day 28, Day 84
Change from baseline in cognitive performance
Symbol Digit Modalities Test (oral SDMT), raw and Z-scores, administered by the study doctor
Measured: Baseline (Day 0), Day 84
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2026
- Study start8 Dec 2025
- Primary completion5 Mar 2026
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin AgeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two-arm parallel group design with 2:1 allocation of participants to the active supplement regimen and the placebo regimen respectively. Each participant received only one regimen for the full 12-week study period.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- IDI Skincare Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Dublin, Trinity College, University of Edinburgh
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07827651
- Sponsor's protocol ID
- IDF_AdvancedID_001
- Other IDs
- 217430
- Acronym
- IDF-AID-1
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-Blind, Randomised, Placebo-Controlled Study Evaluating the Effects of a Novel Multi-Targeted Dermatologist-Formulated Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido, and Longevity
- ClinicalTrials.gov ID
- NCT07827651
- Acronym / sponsor ID
- IDF-AID-1 / IDF_AdvancedID_001
- Conditions
- Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity, Healthspan Improvement, Cognitive Processing Speed
- Keywords
- collagen, dietary supplement, omega-3, skin elasticity, skin hydration, transepidermal water loss, hair density, sleep quality
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 64 participants (actual)
- Lead sponsor
- IDI Skincare LimitedIndustry (pharma, biotech, devices)
- Collaborators
- University of Dublin, Trinity College, University of Edinburgh
- Study start
- 8 Dec 2025 (actual)
- Primary completion
- 5 Mar 2026 (actual)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 18 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the effects of a daily oral supplement regimen (Advanced ID Brain, Heart and Eye Omega Gel Capsules taken with Advanced ID Longevity and Collagen Complex Powder) on measures of skin condition, hair, sleep, energy, cognition and sexual wellbeing in healthy adults aged 35 to 65 years.
Participants were randomised in a 2:1 ratio to receive either the active supplement regimen or a matched placebo regimen once daily with food for 12 weeks. Instrumental skin measurements, trained-assessor visual grading and participant questionnaires were performed at baseline (Day 0), Day 28 and Day 84. Hair imaging and cognitive testing were performed at baseline and Day 84. Whole blood samples were collected at baseline and Day 84 for exploratory epigenetic DNA biological clock age analysis, reported separately.
The study was single-centre, sponsored by IDI Skincare Limited and conducted by Eurofins Product Testing Services Ltd (trading as Eurofins Alba) in Edinburgh, United Kingdom.
Detailed description
Study conduct
The study was conducted at a single centre over 12 weeks with three clinic visits: baseline (Day 0), Day 28 and Day 84. At each of the first two visits participants received a four-week supply of their allocated study products together with a diary sheet to record daily consumption and compliance. Participants consumed their allocated products once daily in the morning with food at home. An acclimatisation period preceded instrumental measurements and imaging at each assessment visit. Adverse events were recorded throughout the study period.
Randomisation and blinding
The randomisation schedule was generated by an independent statistician using product codes only, via a centralised electronic randomisation system, with provision for emergency unblinding. Participants and assessors remained blinded to allocation throughout. Analysts were blinded to product identity at the time of statistical analysis.
Sample size
Enrolment of a minimum of 60 healthy participants was planned in order to complete with a minimum of 50 evaluable participants, targeting a 2:1 completion ratio between the active and placebo groups. The sample size was set on feasibility grounds rather than by formal power calculation.
Statistical analysis
Quantitative responses were modelled as within-subject changes from baseline using mixed models with subject as a random effect, fitted in R, with covariates comprising baseline response level, time, product and their interaction. Handling of baseline measures followed European Medicines Agency (2013) guidance. Where only a single post-baseline measure existed, a simple linear model was fitted. Questionnaire data were analysed non-parametrically where distributional assumptions were violated. Statistical significance was defined at the 5% level. No adjustment for multiple comparisons was applied, and results should be interpreted accordingly given the number of endpoints assessed.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Two-arm parallel group design with 2:1 allocation of participants to the active supplement regimen and the placebo regimen respectively. Each participant received only one regimen for the full 12-week study period.
| Arm | Type | Receives |
|---|---|---|
| Advanced ID Longevity and Collagen Complex Powder | Experimental | Dietary Supplement: Advanced IDTwo Advanced ID Brain, Heart and Eye Omega Gel Capsules followed by approximately 12 g (one scoop) Advanced ID Longevity and Collagen Complex Powder mixed with 400 ml water, taken orally once daily in the morning with food for 12 weeks. |
| Placebo Control | Placebo comparator | Dietary Supplement: Placebo ControlTwo VitaMinute (brand name) Organic Virgin Coconut Oil Softgel Capsules followed by approximately 12 g (one scoop) maltodextrin mixed with 400 ml water, taken orally once daily in the morning with food for 12 weeks. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Healthy adults aged 35 to 65 years (30% male : 70% female desired)
- In generally good health, as determined by medical history questionnaire
- Free from excessive hair, tattoos, dermatitis or scars on the test areas; males must attend each visit clean shaven, having shaved the day before the appointment
- Able to read, understand and sign an informed consent agreement
- Able to communicate well with study personnel and comply with study requirements
Key exclusion criteria (32 listed)
- - Pregnant, breastfeeding, or of childbearing potential and not using reliable contraception
- Consumed any food or health supplements (including vitamins, creatine, omegas, collagen) within the 3 months prior to baseline
- Known allergy or hypersensitivity to any study product ingredient (products contain fish and coconut ingredients)
- Known allergy or hypersensitivity to any dietary supplements
- Any systemic condition (acute or chronic) or skin disorder including eczema, psoriasis, acne or diabetes (inactive skin disease for at least 6 months prior to baseline may be accepted at the Project Manager's discretion)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Advanced IDAlso: Advanced ID Brain, Heart and Eye Omega Gel Capsules, Advanced ID Longevity and Collagen Complex PowderCombined regimen of Advanced ID Brain, Heart and Eye Omega Gel Capsules and Advanced ID Longevity and Collagen Complex Powder. Contains marine collagen (fish) and bovine gelatine. | Dietary supplement | Advanced ID Longevity and Collagen Complex Powder |
| Placebo ControlVirgin coconut oil softgel capsules and maltodextrin powder, matched in presentation to the active regimen. | Dietary supplement | Placebo Control |
Primary outcome
Change from baseline in skin elasticity
Time frame: Baseline (Day 0), Day 28, Day 84
Measured by Cutometer, left and right cheeks and centre forehead.
Change from baseline in skin firmness
Time frame: Baseline (Day 0), Day 28, Day 84
Measured by Cutometer, left and right cheeks and centre forehead
Change from baseline in skin hydration
Time frame: Baseline (Day 0), Day 28, Day 84
Measured by Corneometer, left and right cheeks and centre forehead
Change from baseline in skin barrier function
Time frame: Baseline (Day 0), Day 28, Day 84
Transepidermal water loss (TEWL) measured by DermaLab SkinLab USB Series TEWL Probe, left and right cheeks and centre forehead
Change from baseline in skin radiance
Time frame: Baseline (Day 0), Day 28, Day 84
Trained assessor global assessment using Visual Analogue Scale. Lower scores indicate greater skin radiance/brightness. Higher scores indicate duller, less radiant skin. Therefore, a reduction from baseline indicates improvement. Minimum value is 0 and maximum is 9.
Change from baseline in fine lines and wrinkles
Time frame: Baseline (Day 0), Day 28, Day 84
Trained assessor grading using Roland Bazin scales for crow's feet wrinkles, crow's feet wrinkle depth and number, forehead wrinkles, glabella wrinkles and underneath eye wrinkles. Higher scores indicate greater wrinkle severity. Therefore, a reduction from baseline indicates improvement. Min value is 0, max is 5-7 (depending on the wrinkle scale assessed).
Change from baseline in hair density
Time frame: Baseline (Day 0), Day 84
C-Cube 2D image acquisition and analysis
Change from baseline in hair shaft thickness
Time frame: Baseline (Day 0), Day 84
C-Cube 2D image acquisition and analysis
Change from baseline in hair count
Time frame: Baseline (Day 0), Day 84
Baseline (Day 0), Day 84
4 secondary outcomes
Change from baseline in sleep quality
Time frame: Baseline (Day 0), Day 28, Day 84
Change from baseline in perceived vitality and energy
Time frame: Baseline (Day 0), Day 28, Day 84
Change from baseline in sexual wellbeing
Time frame: Baseline (Day 0), Day 28, Day 84
Change from baseline in cognitive performance
Time frame: Baseline (Day 0), Day 84
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Skin Ageing
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
RecruitingPhase 3
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Skin Quality
Not yet recruiting
Enhancing the Durability of Thread-Assisted Brow Suspension Through Upper Blepharoplasty-Assisted Ligament Release
Brow Ptosis, Dermatochalasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Advanced ID in people with Skin Ageing and Healthy Ageing, run by IDI Skincare Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in skin elasticity (time frame: Baseline (Day 0), Day 28, Day 84). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.